September 10, 2009 |
New York, NY (September 10, 2009): A new study published in the September 11, 2009 issue of Science by researchers at the NYU School of Medicine reveals a conceptually novel mechanism that plays an important role in making human pathogens like Staphylococcus aureus and Bacillus anthracis resistant to numerous antibiotics. The study led by Evgeny A. Nudler, PhD, The Julie Wilson Anderson Professor of Biochemistry at NYU Langone Medical Center, provides evidence that Nitric Oxide, or NO, is able to alleviate the oxidative stress in bacteria caused by many antibiotics and also helps to neutralize many antibacterial compounds. Eliminating this NO-mediated bacterial defense renders existing antibiotics more potent at lower, less toxic, doses. With infectious diseases the major cause of death worldwide, the study paves the way for new ways of combating bacteria that have become antibiotic resistant.
NO is a small molecule composed of one atom of oxygen and one of nitrogen. It was known as a toxic gas and air pollutant until 1987, when it was first shown to play a physiological role in mammals, for which a Nobel Prize was later awarded. NO has since been found to take part in an extraordinary range of activities including learning and memory, blood pressure regulation, penile erection, digestion and the fighting of infection and cancer. A few years ago, the Nudler’s group from NYU demonstrated that bacteria mobilize NO to defend against the oxidative stress. The new study from the same group supports the radical idea that many antibiotics cause the oxidative stress in bacteria, often resulting in their death, whereas NO counters this effect. This work suggests scientists could use commercially available inhibitors of NO-synthase, an enzyme producing NO in bacteria and humans, to make antibiotic resistant bacteria like MRSA and ANTHRAX more sensitive to available drugs during acute infection.
“Developing new medications to fight antibiotic resistant bacteria like MRSA is a huge hurdle, associated with great cost and countless safety issues,” says Nudler. “Here, we have a short cut, where we don’t have to invent new antibiotics. Instead, we can enhance the activity of well established ones, making them more effective at lower doses.”
“We are very excited about the potential impact of this research in terms of continuing to push the boundaries of research in the area of infectious diseases,” said Vivian S. Lee, MD, PhD, MBA, vice dean for science, senior vice president and chief scientific officer of NYU Langone Medical Center. “With the emergence of drug resistant bacteria, it’s imperative that researchers strive to find conceptually new approaches to fight these pathogens.”
The study by Nudler and his colleagues was funded by a 2006 Pioneer Award from the National Institutes of Health in Bethesda, Maryland. The Pioneer Award, a $2.5 million grant over five years, is designed to support individual scientists of exceptional creativity who propose pioneering and possibly transforming approaches to major challenges in biomedical and behavioral research.
Co-authors of the study include Drs Ivan Gusarov and Konstantin Shatalin of the department of biochemistry at NYU School of Medicine in New York.
About NYU Langone Medical Center
Located in the heart of New York City, NYU Langone Medical Center is one of the nation’s premier centers of excellence in health care, biomedical research, and medical education. For over 168 years, NYU physicians and researchers have made countless contributions to the practice and science of health care. Today the Medical Center consists of NYU School of Medicine, including the Smilow Research Center, the Skirball Institute of Biomolecular Medicine, and the Sackler Institute of Graduate Biomedical Sciences; the three hospitals of NYU Hospitals Center, Tisch Hospital, a 726-bed acute-care general hospital, Rusk Institute of Rehabilitation Medicine, the first and largest facility of its kind, and NYU Hospital for Joint Diseases, a leader in musculoskeletal care; and such major programs as the NYU Cancer Institute, the NYU Child Study Center, and the Hassenfeld Children’s Center for Cancer and Blood Disorders.